Sattva S Neelapu Selected Research

Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)

1/2022	SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.
1/2022	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
1/2022	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
1/2022	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.
1/2021	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma.
1/2021	Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma.
1/2020	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.
1/2020	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
1/2020	The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
12/2019	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sattva S Neelapu Research Topics

Disease

70	Neoplasms (Cancer) 12/2022 - 09/2002
41	Lymphoma (Lymphomas) 10/2022 - 12/2004
40	B-Cell Lymphoma (Lymphoma, B Cell) 10/2022 - 08/2012
33	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 03/2004
15	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 09/2002
14	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 08/2012
13	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2007
12	Cytokine Release Syndrome 10/2022 - 01/2017
8	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 12/2010
7	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 11/2009
6	cell-associated neurotoxicity 11/2021 - 06/2019
6	Inflammation (Inflammations) 01/2021 - 11/2009
4	Melanoma (Melanoma, Malignant) 01/2022 - 02/2008
4	Disease Progression 11/2021 - 06/2009
4	Leukemia 01/2020 - 12/2017
4	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2020 - 08/2012
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 09/2002
4	Multiple Myeloma 01/2016 - 09/2002
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 02/2016
2	Arthritis (Polyarthritis) 12/2022 - 01/2019
2	Exanthema (Rash) 01/2022 - 11/2015
2	Acute Lung Injury 01/2021 - 01/2019
2	Sepsis (Septicemia) 01/2021 - 01/2019
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020 - 01/2019
2	Pneumonia (Pneumonitis) 01/2020 - 10/2019
2	Colitis 10/2019 - 01/2019
2	Communicable Diseases (Infectious Diseases) 12/2014 - 02/2008
2	Infections 01/2014 - 07/2012

Drug/Important Bio-Agent (IBA)

29	Chimeric Antigen ReceptorsIBA 10/2022 - 01/2017
27	Rituximab (Mabthera)FDA Link 01/2022 - 06/2006
23	axicabtagene ciloleucelIBA 10/2022 - 01/2017
21	AntigensIBA 01/2020 - 09/2002
20	VaccinesIBA 12/2021 - 09/2002
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2002
10	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 09/2002
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 02/2004
8	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2014
7	fludarabineIBA 01/2022 - 02/2004
7	Lenalidomide (CC 5013)FDA Link 01/2022 - 07/2012
7	CytokinesIBA 06/2021 - 12/2004
5	Monoclonal AntibodiesIBA 01/2022 - 01/2014
5	Cancer VaccinesIBA 01/2018 - 09/2002
5	EpitopesIBA 01/2016 - 06/2006
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2016 - 06/2006
5	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 07/2011 - 06/2006
4	Biomarkers (Surrogate Marker)IBA 12/2022 - 09/2015
4	ibrutinibIBA 12/2020 - 02/2016
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 02/2007
4	ChemokinesIBA 01/2018 - 10/2004
4	Peptides (Polypeptides)IBA 01/2016 - 03/2004
4	Immunoglobulin Idiotypes (Idiotype, Immunoglobulin)IBA 09/2011 - 01/2007
3	pembrolizumabIBA 01/2022 - 09/2015
3	EnzymesIBA 01/2022 - 11/2009
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 01/2020
3	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2021 - 11/2016
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2015
3	Phosphotransferases (Kinase)IBA 01/2021 - 10/2012
3	ibritumomab tiuxetan (Zevalin)FDA Link 01/2021 - 06/2012
3	Histone Deacetylases (Histone Deacetylase)IBA 11/2020 - 11/2009
3	tisagenlecleucelIBA 12/2019 - 01/2018
3	Methotrexate (Mexate)FDA LinkGeneric 10/2018 - 06/2008
3	AntibodiesIBA 01/2018 - 01/2014
3	DNA VaccinesIBA 01/2018 - 11/2007
3	Biological ProductsIBA 01/2017 - 09/2015
3	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2016 - 09/2011
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 01/2018
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2017
2	CD40 Ligand (CD40L)IBA 01/2021 - 06/2013
2	MTOR InhibitorsIBA 11/2020 - 12/2010
2	Histone Deacetylase InhibitorsIBA 11/2020 - 11/2009
2	Bleomycin (Blenoxane)FDA LinkGeneric 07/2020 - 05/2012
2	Pharmaceutical PreparationsIBA 12/2019 - 01/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2019 - 01/2019
2	Pentostatin (Nipent)FDA LinkGeneric 01/2019 - 06/2015
2	NivolumabIBA 01/2019 - 09/2015
2	AnthracyclinesIBA 01/2019 - 03/2015
2	InterferonsIBA 01/2017 - 01/2016
2	idelalisibIBA 01/2017 - 05/2015
2	Bendamustine Hydrochloride FDA Link 11/2016 - 09/2013
2	Bortezomib (Velcade)FDA Link 02/2016 - 01/2013
2	Interleukin-2 (IL2)IBA 01/2016 - 06/2007
2	liposomal doxorubicin (Doxil)FDA Link 11/2015 - 03/2015
2	Vincristine (Oncovin)FDA LinkGeneric 11/2015 - 03/2015
2	pidilizumabIBA 09/2015 - 01/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2015 - 05/2012
2	SGI 1776IBA 09/2013 - 10/2012
2	AutoantigensIBA 05/2013 - 09/2002
2	Oncogene Proteins (Oncogene Protein)IBA 10/2012 - 08/2012
2	Adenosine Triphosphate (ATP)IBA 07/2012 - 12/2010
2	NeurotoxinsIBA 11/2010 - 11/2009
2	Neoplasm Antigens (Tumor Antigens)IBA 02/2008 - 06/2007
2	Carrier Proteins (Binding Protein)IBA 01/2007 - 06/2006

Therapy/Procedure

66	Therapeutics 12/2022 - 09/2005
21	Immunotherapy 01/2022 - 09/2002
20	Drug Therapy (Chemotherapy) 01/2022 - 12/2004
9	Radiotherapy 10/2021 - 10/2014
5	Stem Cell Transplantation 01/2019 - 06/2008
3	Transplantation 01/2021 - 11/2010
2	Combined Modality Therapy 01/2021 - 07/2020
2	Cell Transplantation 01/2021 - 12/2019